20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Glancy Prongay & Murray LLP ("GPM") reminds investors of the October 23, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Teva Pharmaceutical Industries Ltd. ("Teva" or the "Company") (NYSE:TEVA) securities between November 15, 2016 and August 2, 2017, inclusive (the "Class Period"). Teva investors have until October 23, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Teva case page on our website at www.glancylaw.com/case/teva-pharmaceutical-industries-ltd
Investors suffering losses on their Teva investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.
On August 2, 2016, Teva finalized its acquisition of Allergan plc's generics business, Actavis Generis. Thereafter, Teva continued to make positive statements concerning the integration of the business, growth on intangible assets and goodwill, and general benefits of the acquisition. However, on August 3, 2017, Teva lowered its outlook and recorded a $6.1 billion impairment charge.
On this news, Teva's stock price fell $7.50 per share, or 24%, to close at $23.75 on August 3, 2017, thereby injuring investors.
The complaint filed in this class action alleges that throughout the class period the Company issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company's business and outlook. Specifically, the complaint alleges that Teva failed to disclose the negative impact that the acquisition and integration of Actavis Generics was having on the Company's financial results and business prospects.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased shares of Teva during the Class Period you may move the Court no later than October 23, 2017 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171023006144/en/
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!